Early effective treatment may protect from cognitive decline in paediatric multiple sclerosis

Cognitive impairment (CI) is a critical feature for patients with childhood or juvenile multiple sclerosis (MS). To promote the understanding of CI and to address the impact of different pharmacological treatment strategies on cognitive performance in this patient group. A cohort of 19 patients with...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	European journal of paediatric neurology Ročník 23; číslo 6; s. 783 - 791
Hlavní autoři:	Johnen, A., Elpers, C., Riepl, E., Landmeyer, N.C., Krämer, J., Polzer, P., Lohmann, H., Omran, H., Wiendl, H., Göbel, K., Meuth, S.G.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Elsevier Ltd 01.11.2019
Témata:	Adjuvants, Immunologic - therapeutic use Adolescent Child Cognition Cognitive Dysfunction - etiology Cognitive Dysfunction - prevention & control Cohort Studies Disease-modifying drugs Executive Function - drug effects Female Humans Interferon beta-1a - therapeutic use Juvenile multiple sclerosis Male Multiple Sclerosis - complications Multiple Sclerosis - drug therapy Neuropsychological Tests Neuropsychology Paediatric multiple sclerosis Treatment Treatment Outcome Juvenile multiple sclerosis Cognition Treatment Neuropsychology Paediatric multiple sclerosis Disease-modifying drugs
ISSN:	1090-3798, 1532-2130, 1532-2130
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!